Two-year persistent painful bilateral gynaecomastia — tamoxifen course, surgical plan and cancer counselling

Stem and task

A 32-year-old man with 2 years of painful bilateral glandular enlargement persists after cimetidine cessation 6 months ago, with benign bilateral examination, normal genitalia and testicular ultrasound, and no laboratory cause. He wants tamoxifen, surgery details, and cancer-risk counselling. Work through the persistent-disease ladder, operative plan, and boundary.

Model management

Confirm persistence after cause removal and watchful waiting

• He fits long-standing disease: glandular proliferation with fat deposition from oestrogen-androgen imbalance, now 2 years persistent despite removal of a definite drug cause.^[2][8]
• Cimetidine sits on the definite list with spironolactone, ketoconazole, hGH, estrogens, hCG, anti-androgens, GnRH analogs and 5-α reductase inhibitors — stopping it was correct, and watchful waiting after discontinuation was the mandated next step.^[8][1]
• Six months of waiting without regression moves him past observation: surgery is suggested only for long-lasting disease that does not regress spontaneously or following medical therapy.^[1]

Offer tamoxifen for painful disease with honest numbers

• Painful idiopathic or physiological disease is the tamoxifen population: 10 mg for 3 months in the studied regimen.^[9]
• Quote the series: 13 men at median age 36, 10 responded well, one stopped for calf tenderness — safe and effective as an initial option before surgery.^[9]
• Set the guideline frame alongside: routine SERMs, aromatase inhibitors and non-aromatizable androgens are not justified in general, with testosterone only for proven deficiency — his trial is for painful persistent disease, not indefinite hormonal manipulation.^[1]
• If pain persists or fibrous gland remains after the course, move to surgery rather than repeating courses indefinitely.^[1][2]

Plan surgery as liposuction plus adenectomy with grade-appropriate technique

• For long-standing disease the best results combine liposuction and mammary adenectomy — plan both fat and gland tools.^[2]
• Counsel the operative scale: 70 mastectomies in 52 subjects at mean age 47 years, with resected volume rising from 97.4 cm3 to 186.5 cm3 under the extended-visibility double-donut approach for grades II-III disease.^[14]
• Quote safety and satisfaction: no nipple-areola necrosis and no wound-infection complication with 98% cosmetic satisfaction — the mastopexy-plus-skin-reduction design trades a larger hidden incision for contour.^[14]

Close with the cancer boundary

• State plainly: male breast cancer is rare and gynaecomastia should not be considered premalignant — his 2-year gland is not a cancer precursor.^[1]
• Contrast the real cancer picture: peak at 71 years, usually a lump or nipple inversion presenting late with more than 40% stage III-IV disease, BRCA2 over BRCA1 families, with Klinefelter, gonadal dysfunction, obesity, alcohol and radiation but not gynaecomastia raising risk.^[16]
• Safety-net without over-imaging: no routine surveillance mammography for his benign bilateral disease; return for dominant mass, nipple inversion, skin change, bloody discharge or rapid unilateral growth, which would trigger imaging and direct core biopsy.^[1]